Today on Drug Discovery & Development
The oral exposure challenge in PROTACs: What drug developers need to solve early
Proteolysis Targeting Chimera (PROTAC) drugs have evolved from a promising concept to a clinically validated modality. In May 2026, the U.S. FDA approved vepdegestrant (Veppanu®), the first PROTAC drug, marking an important milestone for targeted protein degradation and reinforcing the approach across a multitude of disease areas. PROTACs usually consist of three parts: a target-binding…
AbbVie’s Maviret cured 96% of HCV trial participants. The real world is more complicated.
An estimated 69,000 Americans acquired hepatitis C in 2023, roughly double the mid-2010s rate, even though the disease has been curable with an eight- to 12-week course of oral antivirals for more than a decade. AbbVie’s MAVYRET became the first of those antivirals cleared for acute infection in June 2025, with a 96% cure rate in trial. In the EU,…
Drug Discovery and Development See More >
FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide
In April, The New York Times proclaimed that a gen-AI-driven company that hawked compounded GLP-1 drugs was potentially on track to have $1.8 billion in 2026 sales. The paper also reported that the company, MEDVi, had generated $401 million in sales in 2025, saying it had been given access to unspecified company financials. By then,…
As 59% fewer pharma companies cut staff in Q2 in 2026, job postings rise 15%
Sai Life Sciences’ bet on information-dense scale-up and how it is responding to pharma clients who want acceleration
Ahead of PharmSci 360, DigiM CEO on turning hidden microstructures into drug-release predictions
CEO of CDMO AustinPx on its exclusive agreement with Thermo Fisher’s Patheon division
Sponsored Content See More >
Top Automated Dispensing Cabinets for Pharmacies: Leading Brands ComparedSimplifying workflows is essential. Individuals in the pharmacy industry may accomplish more work with fewer errors by automating medication distribution.…
How Endogenous Tagging is Reshaping Protein AnalysisUnderstanding how proteins behave inside living cells is essential for modern drug discovery. Yet many widely used approaches, particularly plasmid…
What sets oncology biosimilars apart: Anticipating key challenges in the development landscapeBy Kimberly Salgado, ICON plc Advancements in biologic therapies have greatly improved our ability to treat cancer over the last…
Advancing Pressure Protection in Biopharma: How Integrated Bypass Technology Elevates Single-Use Pump Designby Michael Irving, Xylem In pharmaceutical and biopharmaceutical manufacturing, there is zero margin for error when it comes to process…
Complexity’s counterpoint: Understanding protocol optimization In recent years, the clinical research landscape has been marked by a steady rise in protocol complexity with more endpoints…
Optimizing Data Pipelines in Life Sciences with AI-Driven Integration and FHIRSponsored by Infor. Data management in life sciences is inherently complex. Data is fragmented across multiple systems — such…
Accelerating life sciences with AI This case study is sponsored by Infor. Artificial intelligence can revolutionize clinical interoperability by building bridges across data silos. Machine…
Advancing Clinical Trials and ResearchThis case study is sponsored by Infor. In the complex landscape of clinical trials and medical research, data fragmentation remains…
Multidisciplinary approaches optimize contract drug discovery
5 Key Questions in Conducting Global Usability StudiesBy Dr Bryce G Rutter, Head Noble Consulting Services Evaluating device usability throughout the product development process is crucial. A…
Leveraging HF/UX/ID Services to Optimize the Design of Combination Devices for Arthritic HandsBy Dr. Bryce G Rutter, Head of Consulting Services Arthritis changes how people grasp and manipulate an object, reducing the…
Ask the Expert: Navigating the New FDA Rules on Laboratory Developed Tests (LDTs)The U.S. FDA released a final rule to regulate laboratory developed tests (LDTs) on May 6, 2024, making it clear…
Genomics/Proteomics See More >
New cell imaging method reveals hidden enzyme activity
Negative biosensors have often been unusable because, as the sensors lose signal when activity is detected, regions of high enzyme activity can look identical to regions with no activity. Researchers at the University of Illinois Chicago have solved this problem with a new cell imaging method that allows scientists to see previously hidden enzyme activities by flipping the optical readout of…
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Spatial biology: Transforming our understanding of cellular environments
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Infectious Disease See More >
AbbVie’s Maviret cured 96% of HCV trial participants. The real world is more complicated.
An estimated 69,000 Americans acquired hepatitis C in 2023, roughly double the mid-2010s rate, even though the disease has been curable with an eight- to 12-week course of oral antivirals for more than a decade. AbbVie’s MAVYRET became the first of those antivirals cleared for acute infection in June 2025, with a 96% cure rate in trial. In the EU,…
FDA greenlights ViiV’s Tivicay PD for HIV-positive newborns in first month of life
As measles cases hit a 35-year high, Trump executive order backs a narrower childhood vaccine list
AbbVie’s Maviret ends the wait-and-see reality for acute HCV
Weekly Gilead and Merck oral HIV regimen maintains suppression in two phase 3 trials
Oncology See More >
Merck and Moderna’s cancer vaccine is customized for each patient’s tumor
A new investigational cancer vaccine developed by Merck & Co. and Moderna is customized based on the genome of each patient’s tumor, designed to teach their immune system to recognize the cancer as a foreign body. The companies are investigating the vaccine as a combination treatment with Merck’s Keytruda, a monoclonal antibody that targets the PD-1 receptor on T-cells, breaking a pathway…
As chemo overtreatment comes into focus, Atossa bets on tamoxifen’s active form
How ConcertAI turned CancerLinQ into a point-of-care oncology intelligence platform
Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform
